Show simple item record

dc.contributor.authorJones, JR
dc.contributor.authorBarber, A
dc.contributor.authorLe Bihan, Y-V
dc.contributor.authorWeinhold, N
dc.contributor.authorAshby, C
dc.contributor.authorWalker, BA
dc.contributor.authorWardell, CP
dc.contributor.authorWang, H
dc.contributor.authorKaiser, MF
dc.contributor.authorJackson, GH
dc.contributor.authorDavies, FE
dc.contributor.authorChopra, R
dc.contributor.authorMorgan, GJ
dc.contributor.authorPawlyn, C
dc.date.accessioned2021-10-26T08:51:44Z
dc.date.available2021-10-26T08:51:44Z
dc.identifier.citationLeukemia, 2021, 35 (10), pp. 3017 - 3020
dc.identifier.issn0887-6924
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4844
dc.identifier.eissn1476-5551
dc.identifier.doi10.1038/s41375-021-01373-4
dc.formatPrint-Electronic
dc.format.extent3017 - 3020
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleMutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
dc.typeJournal Article
dcterms.dateAccepted2021-07-27
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41375-021-01373-4
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLeukemiaen_US
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.publication-statusPublished
pubs.volume35en_US
pubs.embargo.termsNot known
icr.researchteamMyeloma Biology and Therapeutics
icr.researchteamTarget Evaluation and Molecular Therapeutics
icr.researchteamHit Discovery & Structural Design
dc.contributor.icrauthorWang, Hannahen_US
dc.contributor.icrauthorPawlyn, Charlotteen_US
dc.contributor.icrauthorLe Bihan, Yann-Vaien_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0